A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease
Open Access
- 20 June 2013
- journal article
- biology
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 19 (9), 1323-1330
- https://doi.org/10.1016/j.bbmt.2013.06.011
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intakeNature, 2012
- Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patientsBone Marrow Transplantation, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationThe New England Journal of Medicine, 2010
- Elafin Is a Biomarker of Graft-Versus-Host Disease of the SkinScience Translational Medicine, 2010
- TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokinesEuropean Journal of Immunology, 2009
- A biomarker panel for acute graft-versus-host diseaseBlood, 2009
- TIMs: central regulators of immune responsesThe Journal of Experimental Medicine, 2008
- TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cellsBlood, 2007
- Dysregulated T cell expression of TIM3 in multiple sclerosisThe Journal of Experimental Medicine, 2006